Qpain® is a new topical anti-inflammatory cutaneous solution, containing diclofenac sodium 1.5% w/w, indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee. – Qpain® contains DMSO which enhances the absorption of diclofenac from the skin and reaches the focus of pain and inflammation directly. Ideal for those who cannot [...]
26.09.2023, Divani Caravel Hotel Athens Greece The Pharmaceutical Industry in Greece has completed 90 years since its foundation in 1933 as the Union of Pharmaceutical Laboratories which evolved into the Panhellenic Association of the Pharmaceutical Industry (P.E.F.). On Tuesday, 26.09.23, at a brilliant anniversary event at the "Divani Caravel" hotel, Panhellenic Association of Pharmaceutical Industries [...]
22 – 24/09/2023 Hermes Hotel, ERMOUPOLIS, SYROS ISLAND IASIS PHARMA participated in the "Developments in Dermatology & Venereology 2023" conference which held on September 22-24 2023, at the Hermes Hotel in Syros Island. The conference was organized by the Hellenic College of Dermatology-Venereology with the scientific support of the 2nd Clinic of Venereology and Skin [...]
Grecotel Filoxenia, Kalamata, 14-17/09/2023 During 14-17/09/2023, at Grecotel Filoxenia/KALAMATA, the Society for the Study of Dermatovenereologic and Allergic Diseases (S.S.D.A.D.) organized the 6th Panhellenic Conference “Dermatological diseases: Past, present and future”. Dermatologists from all over Greece who attended the Conference had the chance to visit IASIS PHARMA exhibition stand and received information about IASIS major Dermatological products: Isotroin®/Isotretinoin (in the new & [...]
Divani Caravel, Athens, 09-11/06/2023 IASIS PHARMA participated in the dermatological conference "ATTICA DERMATOLOGY DAYS", which was held on June 09-11, 2023, at the Divani Caravel hotel /Athens. The conference, which organized by the Hellenic College of Dermatology-Venereology, with the scientific support of the 2nd Clinic of Dermatology and Venereal Diseases EKPA, mainly concerned at the central [...]
IASIS PHARMA is pleased to announce the Nitrofurantoin/IASIS oral susp. launching in the oral suspension formulation. This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A. Each 5ml of oral suspension Nitrofurantoin/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature, [...]
On Saturday, April 29th 2023, the Mastic Research Center (M.R.C.) opening was held in Kallimasia of Chios. Many people was present such as from the medical, pharmaceutical, business, political and academic field, as well as the mastic producers and guests. This project will be a reliable body that will coordinate academic interests and scientific research [...]
Divani Caravel Hotel, Athens, 8-11/03/2023 IASIS PHARMA participated in the 21st National Diabetes Congress, showing its active interest in Diabetes Mellitus disease, promoting cornerstone pharmaceutical products for type 2 diabetes. Moreover, IASIS PHARMA is about to invest significantly in T2DM in the near future, launching more than 4 original products. The conference took place on [...]
February 15, 2023 Royal Olympic Hotel - Athens, Electra Palace Hotel - Thessaloniki IASIS PHARMA, having successfully completed the Research and Development of Isotretinoin soft gel caps in the new strength of 30 mg, announced the release of the new & unique Isotroin 30mg. This consists of the most appropriate pharmaceutical option for the treatment [...]
The Met Hotel, Thessaloniki, 16-18/02/2023 IASIS PHARMA participated in the Working Groups of the Hellenic Society of Cardiology, thus expressing its active interest in the specialty of Cardiology, in which the company operates with original & generic medicines. The event took place on February 16-18, 2023, at the Met Hotel in Thessaloniki, with the participation [...]
